Volume 10, Number 1—January 2004
Research
Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection
Table 3
Diagnosis | HTLV seronegative (N = 799) | HTLV-I (N = 152) | HTLV-II (N = 387) | ||||
---|---|---|---|---|---|---|---|
ID (SD) | ID (SD) | RRb | Adj. RR (95% CI)c | ID (SD) | RRb | Adj. RR (95% CI)c | |
Pneumonia | 0.08 (0.37) | 0.11 (0.47) | 1.49 | 1.33 (0.66 to 2.66) | 0.21 (0.96) | 2.82 | 2.65 (1.67 to 4.21) |
Acute Bronchitis | 0.59 (1.78) | 0.82 (2.25) | 1.38 | 1.33 (0.84 to 2.12) | 1.10 (2.75) | 1.83 | 1.53 (1.10 to 2.14) |
Bladder or Kidney infection | 0.63 (2.04) | 1.75 (4.61) | 2.73 | 2.32 (1.50 to 3.59) | 1.25 (3.48) | 1.94 | 1.94 (1.40 to 2.68) |
aDefined as the mean of the total number of infectious disease diagnoses divided by the number of participants (with or without the infection) in each group at baseline. The period of observation was 4.4 years (HTLV-I), 4.3 years (HTLV-II), and 4.4 years (HTLV seronegative), and each participant may have multiple diagnoses of each condition.bUnadjusted.
cAdjusted. Adjusted models included age, gender, race/ethnicity and duration of follow-up for all infections, and injection drug use (for pneumonia), smoking (for acute bronchitis), and community versus autologous blood donation (for bladder/kidney infection).
Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.